AnaMar Medical

Executive Summary

AnaMar Medical is a clinical-stage biotechnology company based in Lund, Sweden, dedicated to developing novel therapies for fibrotic diseases. Its lead candidate, AM1476, is a first-in-class, orally bioavailable, peripherally-acting 5-HT2B receptor antagonist designed to prevent, heal, and slow organ scarring. The company's initial focus is on systemic sclerosis (SSc), a severe autoimmune disease with high unmet need, where AM1476 has demonstrated dual-action potential to treat both skin and lung fibrosis in preclinical models. As a private, preclinical-stage company, AnaMar is positioned to address a significant market in fibrosis, with SSc affecting approximately 100,000 patients in the US and EU. AnaMar Medical is advancing AM1476 toward clinical development, with key milestones expected in the near term. The company plans to submit an Investigational New Drug (IND) application in the coming months, followed by initiation of a Phase 1 clinical trial in healthy volunteers. Pending successful safety and tolerability data, the program could rapidly progress to Phase 2 proof-of-concept studies in systemic sclerosis patients. Additional preclinical data, including biomarker and efficacy results, are anticipated to support the therapeutic rationale. With a strong scientific foundation and a clear regulatory path, AnaMar represents a promising investment opportunity in the fibrosis space, though valuation and financing details remain undisclosed.

Upcoming Catalysts (preview)

• Q2 2026IND Submission for AM147690% success
• Q4 2026Initiation of Phase 1 Clinical Trial70% success
• Q3 2026Presentation of Preclinical Data at Major Conference95% success